FC receptor (FcRn) binding peptides and uses thereof

Patent metadata

Field	Value
Publication number	US-9527890-B2
Application number	US-201414897999-A
Country	US
Kind code	B2
Filing date	Jun 18, 2014
Priority date	Jun 18, 2013
Publication date	Dec 27, 2016
Grant date	Dec 27, 2016

Abstract

The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.

First claim

What is claimed is:

1. An isolated polypeptide that specifically blocks the interaction between neonatal Fc receptor (FCRN) and albumin comprising at least one peptide subunit consisting of an amino acid sequence that is at least 90% identical to RYFCTKWKHGWCEEVGT (SEQ ID NO:1).

2. The isolated polypeptide of claim 1 , wherein the at least one peptide subunit consists of the amino acid sequence set forth in SEQ ID NO:1.

3. The isolated polypeptide of claim 1 , comprising two peptide subunits, wherein the peptide subunits consist of an amino acid sequence that is at least 90% identical to SEQ ID NO:1.

4. The isolated polypeptide of claim 1 , comprising four peptide subunits, wherein the peptide subunits consist of an amino acid sequence that is at least 90% identical to SEQ ID NO:1.

5. The isolated polypeptide of claim 3 , wherein the peptide subunits are linked by a linker.

6. The isolated polypeptide of claim 5 , wherein the linker is a peptide linker comprising 1-10 amino acids.

7. The isolated polypeptide of claim 5 , wherein the linker is a glycine linker comprising 1-10 glycine residues (SEQ ID NO: 14), or 1-10 glycine and serine residues (SEQ ID NO: 15).

8. The isolated polypeptide of claim 7 , wherein the glycine linker comprises 3-5 glycine residues (SEQ ID NO: 16), or 3-5 glycine and serine residues (SEQ ID NO: 17).

9. The isolated polypeptide of claim 5 , wherein the linker is formed from a polyethylene glycol (PEG) H—(O—CH 2 —CH 2 ) n —OH, wherein n is an integer from 2-12.

Assignees

• The Brigham And Womens'S Hospital Inc
• Biogen Idec Inc

Inventors

• Blumberg Richard S
• Rath Timo
• Baker Kristi
• Mezo Adam
• Taylor Zachary
• Mcdonnell Kevin
• Grenha Rosa Maria Silva Garcia

Classifications

• C07K14/001 Primary

  by chemical synthesis · CPC title

• C07K14/765

  Serum albumin, e.g. HSA · CPC title

• A61K47/54

  the modifying agent being an organic compound · CPC title

• G01N33/5023

  on expression patterns · CPC title

• C07K2319/31

  fusions, other than Fc, for prolonged plasma life, e.g. albumin · CPC title